Praxis Precision Medicines Files 8-K

Ticker: PRAX · Form: 8-K · Filed: Oct 21, 2025 · CIK: 1689548

Praxis Precision Medicines, Inc. 8-K Filing Summary
FieldDetail
CompanyPraxis Precision Medicines, Inc. (PRAX)
Form Type8-K
Filed DateOct 21, 2025
Risk Levellow
Pages3
Reading Time3 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, SEC filing, financial-statements

TL;DR

Praxis Precision Medicines filed an 8-K on 10/20/25, mostly financial docs & other events.

AI Summary

On October 20, 2025, Praxis Precision Medicines, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific financial figures or material events beyond the filing itself were detailed in the provided text.

Why It Matters

This 8-K filing indicates that Praxis Precision Medicines is providing updated information to the SEC, which could include material disclosures relevant to investors.

Risk Assessment

Risk Level: low — The provided text is a standard 8-K filing notification and does not contain specific material events or financial data that would indicate a high risk.

Key Players & Entities

  • Praxis Precision Medicines, Inc. (company) — Registrant
  • 0001689548-25-000103 (other) — Accession Number
  • October 20, 2025 (date) — Date of earliest event reported
  • Boston, Massachusetts (location) — Principal executive offices

FAQ

What is the primary purpose of this 8-K filing?

The 8-K filing is intended to report on Other Events, Regulation FD Disclosure, and Financial Statements and Exhibits.

What is the exact date of the earliest event reported in this filing?

The date of the earliest event reported is October 20, 2025.

What is the company's principal executive office address?

The company's principal executive office is located at 99 High Street, 30th Floor, Boston, Massachusetts 02110.

What is the company's telephone number?

The company's telephone number is (617) 300-8460.

What is the SIC code for Praxis Precision Medicines, Inc.?

The Standard Industrial Classification (SIC) code for Praxis Precision Medicines, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 779 words · 3 min read · ~3 pages · Grade level 11.6 · Accepted 2025-10-21 08:02:31

Key Financial Figures

  • $0.0001 — ge on which registered Common Stock, $0.0001 par value per share PRAX The Nasdaq Glo

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On October 21, 2025, Praxis Precision Medicines, Inc. (the "Company") updated its corporate presentation for use in meetings with investors, analysts and others. The presentation is available in the "Investors + Media" portion of the Company's website at investors.praxismedicines.com and a copy is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the "Current Report"). The information in this Current Report under Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01. Other Events

Item 8.01. Other Events. As previously disclosed, the Company submitted a pre-NDA meeting request to the U.S. Food and Drug Administration (the "FDA") for ulixacaltamide. On October 20, 2025, the Company was informed by the FDA that, following its review of the Essential3 topline results, the FDA granted a Type B meeting to take place in the fourth quarter of 2025.

Forward-Looking Statements

Forward-Looking Statements This Current Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the anticipated timing of regulatory interactions for ulixacaltamide. The forward-looking statements included in this Current Report are subject to a number of risks, uncertainties and assumptions, including, without limitation, uncertainties inherent in clinical trials, the expected timing of submission for regulatory approval or review by governmental authorities and other risks as described in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 and its other filings with the Securities and Exchange Commission. These statements are based only on facts currently known by the Company and speak only as of the date of this Current Report. As a result, you are cautioned not to rely on these forward-looking statements and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Praxis Preci sion Medicines, Inc. October 2025 Corporate Presentation 104 Cover Page Interactive Data File (embedded within the inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PRAXIS PRECISION MEDICINES, INC. Date: October 21, 2025 By: /s/ Marcio Souza Marcio Souza Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.